Superdisintegrants Market size is set to gain remarkable traction from 2021 to 2027. This is due to the significant usage of disintegrants and superdisintegrants in tablets to ensure the rapid breakdown into primary particles, thus facilitating the release or dissolution of active ingredients. Likewise, the rising popularity of orally disintegrating tablets (ODTs) in the pharmaceutical and nutraceutical fields to treat patients with dysphagia and other conditions will also contribute to the industry growth during the forecast period. Superdisintegrants refers to substances that can facilitate faster disintegration of capsules with a smaller quantity. This substance, available in natural and synthetic variants, is generally used at a low level in solid dosage variants, which is typically 1% to 10% by weight in relation to the total weight of the drug dosage unit.
Escalating investment activities in healthcare, along with the rising prevalence of cardiovascular diseases, are among the key trends characterizing the overall market outlook over the coming years. The significant growth potential is attributed to the use of both natural and synthetic superdisintegrants in the development of drugs for CVD treatment and other therapeutic areas. In addition, the strong focus on the delivery of patient-centric services and the subsequent rise in the development of solid oral drug formulations will further stimulate the substance demand in the coming years.
On the basis of dosage form, the mouth-dissolving films segment is anticipated to account for a commendable market share by 2027. This is given the emergence of oral dissolving film as a revolutionary technology and approach to nutrient delivery worldwide. Myriad other benefits of this dosage form, including high stability, durability, and faster dissolving capability as compared to other conventional dosage forms, will also expedite market growth from this segment during the forecast timeline.
The North America superdisintegrants market is projected to hold a considerable share in the global market by 2027. This can be credited to the increasing burden of migraine and Alzheimer’s disease in countries such as the U.S., considering the important role of orally disintegrating tablets in the treatment of neurological disorders. Furthermore, the commendable increase in pharmaceutical spending over the past years will further bolster the need for superdisintegrants in the region. According to a Pharmaceutical Commerce report, spending on medicine is expected to reach up to $655 billion in America by 2023, thus contributing to the regional growth.
Key players in the global market include Roquette Freres, DFE Pharma (FrieslandCampina), JRS Pharma, BASF SE, and Ashland, among others. These industry participants are engaging in varied strategies such as collaborations, partnerships, and new product launches to increase profitability and grow across the global market.
The ongoing COVID-19 pandemic significantly impacted the bioanalytical and pharmaceutical communities, particularly in the development of therapeutics and supporting ongoing drug trials. Various existing processes were also challenged in terms of managing the loss of staffing at facilities as well as added workloads for other COVID-19 related support, influencing industry dynamics to a certain extent. However, the rising awareness about the increased risk of coronavirus infection among neurological patients may help revive the industry gradually over the foreseeable future. Among some patients, overreactive response to the virus has been shown to increase the risk of dementia, stroke, vascular disorders, and encephalitis. Since orally disintegrating tablets are used extensively as a treatment option for patients with neurological conditions such as these, drug production is likely to witness a significant boost and in turn, provide a positive growth trajectory for the overall market.
Market, by Product
Market, by Dosage form
Market, by Therapeutic area
The above information is provided for the following regions and countries: